April 29 () - Pfizer said on Wednesday its drug Elrexfio met the main goal in ‌a late-stage trial that tested the blood ...

The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...

April 28 (Reuters) - Pfizer said on Tuesday it has settled patent disputes with three generic drugmakers over its blockbuster ...

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...

Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in ...

Patients taking Pfizer’s Vyndaqel and Vyndamax for a progressive, often fatal form of heart failure will not see cheaper ...

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...

Pfizer (PFE) stock is in focus as a trial for the company's Elrexfio multiple myeloma drug hit the main goal with patients on ...

Lyme disease is the most common tick-borne infectious disease in the United States. There is no vaccine to protect against it in humans. Biopharmaceutical company Pfizer and Valne ...

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.